Solstice Oncology raises a $225M Series A to rebuild CTLA-4 cancer immunotherapy
Solstice Oncology has raised $225 million in Series A funding to develop next-generation CTLA-4 cancer immunotherapy - a first round larger than most companies' growth stages.
